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The timing of initiation of drug therapy in patients newly diagnosed with Parkinson’s disease (PD) has been a subject of some debate. In the absence of any therapy proven to modify disease progression, most clinicians have adopted a “wait and watch” strategy, with initiation of therapy only when there is a perceived symptomatic or functional need.[1] Recently, some experts have questioned this approach and suggested that dopamine replacement therapy should be started as soon as the diagnosis has been made.[2]  Whilst there are no long-term randomised trials comparing early versus delayed initiation of symptomatic treatment, early treatment was supported by one “real life” longitudinal cohort study[3] that found that self reported health status, as measured by PDQ-39,[4] showed significant deterioration in people with early PD left untreated but not in those who received therapy.





As part of a pilot study of the incidence and prognosis of parkinsonian syndromes in Aberdeen,[5] all patients from 18 general practices who presented with a newly diagnosed possible or definite parkinsonian syndrome were identified over an 18 month period. All patients were assessed by a neurologist with a special interest in PD and underwent a standardised baseline assessment including the Unified Parkinson’s Disease Rating Scale (UPDRS),[6] Hoehn & Yahr (H&Y) score[7] and assessment of atypical features, such as dysautonomia, gaze palsy and cognitive or psychiatric symptoms. Parkinsonism was diagnosed when two or more of the cardinal motor signs were present and the cause was diagnosed on clinical grounds without applying specific research criteria, which are difficult to apply in early disease.  Hence, patients were diagnosed with probable PD if they had no atypical features (early dementia or falls, prominent autonomic, pyramidal or cerebellar features, eye movement disorder, isolated lower body parkinsonism etc) or if they had a classical unilateral rest tremor.

Incident patients were offered routine clinical care and also invited to consent to more detailed yearly follow-up, which included assessment of overall health status with the PDQ-39.  Patients could also be seen between yearly visits if there was a clinical need, such as to start treatment.  At each visit the advantages and disadvantages of treatment were discussed so that the decision to start treatment was reached by consensus between the doctor and patient, taking into account factors such as clinical presentation (tremor less likely to respond than rigidity or bradykinesia), the impact of symptoms on the patient’s lifestyle and patient preference. No specific scores (e.g. the PDQ-39) were used to guide the initiation of treatment. There was no standard first line dopaminergic medication and four patients were recruited into the PDMED trial.[8]

For this study, we only included consenting patients with a baseline clinical diagnosis of PD who had at least one year of follow-up.  We compared PDQ-39 and UPDRS at baseline, one and two years between those who had treatment initiated within one year of diagnosis (treated group) and those who remained untreated over the first two years (drug naïve group).  We planned to analyse those in whom treatment was initiated during the second year of follow-up as a separate group, but the numbers were too small and so these patients were excluded.





Of an incident cohort of 82 patients with possible or probable parkinsonism, 52 were given an initial clinical diagnosis of PD, of whom 50 consented to follow-up. Eight were excluded from the current study: three were already taking levodopa at initial assessment (one for restless legs syndrome, two for PD where treatment had been started by the GP and a geriatrician); three died before one year follow-up and two started treatment between their first and second yearly follow-up appointments. 

26 of the remaining 42 patients (62%) patients started taking medication for their PD within the first year of the study, whilst 16 did not receive any anti-parkinsonian medication during the two year follow-up period. Three included patients died between their first and second yearly follow-up appointments. Data for these patients have been included for time points where they were available. 

The characteristics of the drug naïve and treated groups are presented in table 1. The treated group were older, less likely to be male, and had worse depression scores although these differences were not statistically significant. As expected, those receiving treatment in the first year had worse disease at baseline demonstrated by significantly higher UPDRS scores, H&Y, and PDQ-39. 

Of those started on treatment in the first year, 18 (69%) received levodopa alone, 5 (19%) received a dopamine agonist, and three received combination therapy; a dopamine agonist plus selegiline, levodopa plus selegiline, and levodopa plus entacapone. Median LEDD was 400mg (inter-quartile range [IQ] 300 to 519mg) at year 1 and 400mg (IQ 150 to 550mg) at year 2.

Table 1: Patient characteristics at baseline

	Drug-naïve(n=16)	Treated(n=26)	
Mean age in years (SD)	72.5 (11.0)	76.1 (9.2)	
Male gender	68.8%	53.8%	
Total UPDRS 	25 (18 to 34)	46 (38 to 53)	P<0.001
Motor UPDRS 	17 (13 to 26)	31 (27 to 39)	P<0.001
% Hoehn & Yahr I or II	68.8%	38.5%	p=0.06†
GDS-15 	4 (2 to 6)	6 (3 to 8)	
Symptom duration in months 	11.3 (7.1 to 12.4)	12.4 (6.5 to 19.5)	
PDQ-39 summary index 	11.7  (5.5 to 16.8) 	20.2 (16.1 to 33.6)	p=0.001

SD= standard deviation; IQ= inter-quartile range; UPDRS= Unified Parkinson’s disease rating scale; GDS-15= Geriatric depression score, short version; PDQ-39= Parkinson’s disease questionnaire. Data are median with interquartile range unless otherwise stated.
†Chi-squared test

There was no significant difference in the change in the PDQ-39 summary index over two years between the drug naïve (median 0.8, IQ -0.8 to 16.7) and treated groups (median 4.0, IQ -3.4 to 10.6, p=0.47), whilst only two subscores showed significantly greater deterioration in the drug naïve group compared to the treated group (activities of daily living [ADL] 22.9, IQ 4.2 to 50.0 versus 0.0, IQ -16.7 to 16.7, p=0.02; stigma 12.5, IQ 0.0 to 25.0 versus 0.0, IQ -12.5 to 6.3, p=0.03)[Figure 1]. In the drug naïve group, there was significant worsening between baseline and two years in three subscores - mobility (p=0.006), ADL (p=0.005), stigma (p=0.020). There was a significant difference (p=0.03) between the change in motor UPDRS between the drug naïve (median 6; IQ -6 to 15) and treated groups (median -6; IQ -11 to 4). There was no change in median depression score over two years in either group.





As expected, people with PD who chose to start treatment within one year of diagnosis had worse disease in terms of UPDRS impairment scores and PDQ-39 than those who chose to remain untreated.  However, unlike the PDLIFE study, we found no significant deterioration in overall self-reported health status (PDQ-39 summary index) over two years in those who chose not to receive any treatment (despite an objective deterioration in motor impairment measured by UPDRS), whereas those who chose treatment did worsen slightly (despite a response to treatment shown by an improvement in motor UPDRS).  Unlike PDLIFE, we showed only mild worsening in three of the eight subscores of the PDQ-39 in those who remained untreated, and the PDQ-39 subscores after two years follow-up remained lower than the baseline scores of those who were treated.

The main strengths of this study were that the patients were taken from a community-based incident cohort with a low rate of loss to follow-up and so the results are likely to be more representative than those from cohorts from specialist clinics.  However, there are also a number of weaknesses. Firstly, the sample size was small and, therefore, it may have been under powered to detect clinically important changes.  However, the absolute changes seen in the untreated group were all smaller in magnitude than in the PDLIFE study. A larger incidence study is ongoing and so these data will be available for a larger sample size in due course. Secondly, this was a single centre study and so needs to be replicated in other centres. Thirdly, we used a clinical diagnosis of PD rather than strict research criteria such as the UK Brain Bank criteria.  However, we felt this was reasonable because we wished to reflect routine clinical practice and Brain Bank criteria require several supportive criteria that cannot be assessed in the early diagnostic phase of PD.  Finally, as an observational study, this study was not equipped to definitively answer the question of whether early treatment or a “wait and watch” strategy is preferable in early PD. Properly designed, randomised trials will be necessary to resolve the issue.

There may be several reasons why our results were different to the PDLIFE study.  The latter study excluded 42% of patients who were drug naïve at baseline compared to only 14% in our study. This difference was largely because PDLIFE excluded 37% of patients who were started on treatment between baseline assessment and first follow-up (at around 9 months), whereas equivalent patients were included in our treated group. These may have been the more severely affected patients, which may explain why in our study those who received treatment had significantly worse self-reported health status (as measured by PDQ-39) at baseline than those not receiving treatment, whilst this was not the case in PDLIFE.  In addition, our patients were older than in PDLIFE (mean age 74.5 years vs. 63.4 years) and, therefore, the different results in PDQ-39 may reflect different health expectations at different ages.  Lastly, our patients had had their disease for a much shorter time.  Our cohort was followed for two years immediately following initial diagnosis (after a median symptom duration of 12 months). It is not clear whether the mean duration of disease of four years quoted for PDLIFE is taken from symptom onset or from diagnosis, but it would seem that patients were observed three or four years earlier in the disease process in our study.  This may well explain why our untreated patients’ health status deteriorated more slowly than the untreated patients in PDLIFE.
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